Shots:

• Eli Lilly reports additional data on its SARS-CoV-2 neutralizing Ab programs including interim data on combination therapy in diagnosed patients with mild-to-mod. COVID-19 and plans to make therapies available to patients
• The new analysis P-II BLAZE-1 study assessing LY-CoV555 (2800mg) + LY-CoV016 (2800mg) vs PBO demonstrated reduced viral load@11days. meeting its 1EPs- reduction in symptoms and COVID-related hospitalization and ER visits
• Based on the combination regimen data- along with the previous findings for LY-CoV555- Lilly has submitted the initial EUA for LY-CoV555 monothx. and plans to initiate a large open-label pragmatic study in COVID-19 outpatients in Oct’2020. Additionally- Lilly anticipates the data supporting BLA submission for dual regimen as early as Q2’21

­ Ref: Eli Lilly | Image: Eli Lilly